Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133418 | 0.89 | L3MBTL3 (0.51) | FAAHMCHR1L3MBTL3ADRB3TDP2 | |
| SCHEMBL4132414 | 0.89 | HRH3 (0.45) | FAAHL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4135538 | 0.86 | L3MBTL3 (0.53) | L3MBTL3ALDH1A1L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4135754 | 0.86 | HRH3 (0.42) | FAAHL3MBTL3ALDH1A1KDM2B | |
| SCHEMBL4132197 | 0.85 | HRH3 (0.53) | FAAHMCHR1L3MBTL3L3MBTL1 | |
| SCHEMBL4143084 | 0.85 | KCNH2 (0.47) | MCHR1L3MBTL3ALDH1A1L3MBTL1KDM2B | |
| SCHEMBL4145248 | 0.85 | GRIN2B (0.51) | FAAHGRIN2B | |
| SCHEMBL4147479 | 0.84 | FYN (0.44) | FAAHGRIN2B | |
| SCHEMBL4144854 | 0.83 | HRH3 (0.52) | ALDH1A1 | |
| SCHEMBL4141827 | 0.83 | HRH3 (0.49) | FAAHMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | FAAH 217/4885MCHR1 287/4885L3MBTL3 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.